4//SEC Filing
Wilson Mark Andrew 4
Accession 0000950170-24-137544
CIK 0000906709other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 8:54 PM ET
Size
10.7 KB
Accession
0000950170-24-137544
Insider Transaction Report
Form 4
Wilson Mark Andrew
Chief Legal Officer
Transactions
- Award
Stock Option
2024-12-13+331,875→ 331,875 totalExercise: $4.91Exp: 2030-08-14→ Common Stock (331,875 underlying) - Award
Common Stock
2024-12-13+165,938→ 385,294 total - Award
Stock Option
2024-12-13+325,000→ 325,000 totalExercise: $1.01Exp: 2032-12-12→ Common Stock (325,000 underlying)
Footnotes (6)
- [F1]Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on August 15, 2022 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant.
- [F2]The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 18, 2024 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on December 13, 2024 (subject to remaining time-based vesting requirements).
- [F3]This number includes 7,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c).
- [F4]These stock options were granted on August 15, 2022 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant.
- [F5]The Compensation Committee determined on November 18, 2024 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on December 13, 2024 (subject to remaining time-based vesting requirements).
- [F6]Stock options vest over four years from the date of grant, (December 13, 2024) in equal monthly installments based on continued service.
Documents
Issuer
NEKTAR THERAPEUTICS
CIK 0000906709
Entity typeother
Related Parties
1- filerCIK 0001808356
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 8:54 PM ET
- Size
- 10.7 KB